Clinical Case Study: MultiSpecies Probiotic Supplement Minimizes
Symptoms of Irritable Bowel Syndrome
2010/04/30 - UAS Laboratories, Inc.

--------------------------------------------------------------------------------

Twenty-five Patient Case Study using Multi-Flora Probiotics for
reduction of IBS symptoms demonstrated significant improvement in
multiple symptoms.

Eden Prairie, MN 30-April 2010

Physicians from UND School of Medicine and Mayo Clinic conducted a
clinical case study to demonstrate whether using multispecies
probiotic could minimize the symptoms of patients with irritable bowel
syndrome (IBS).   IBS is estimated to affect 20-30% of the population
with 30-50% of gastroenterology referrals related to IBS symptoms.  In
western countries, women are 2-3 times more likely to develop IBS.
The causes of IBS are thought to include cooking.net">food intolerance, imbalance
of intestinal microflora and colonic malfermentation. For standardized
diagnosis for clinical practice, Rome III criteria are used.  Earlier
studies using probiotics as a therapeutic agent have been promising.

Researchers evaluated 25 patients with IBS as defined by Rome III
criteria over a period of 60 days.  Patients were treated with a
multispecies probiotic product (Multi-Flora Plus) containing
Lactobacillus acidophilus DDS?-1 strain, Bifidobacterium longum,
Bifidobacterium bifidum and Bifidobacterium lactis with a combined
potency of 12 billion CFU/g.  Patients symptom severity was evaluated
on a scale of 1 to 10.  Improvement was classified as at least 50%
reduction in severity.  The most significant improvements occurred
after 60 days of treatment with 84% of the patients showing
improvement in abdominal pain, 73.9% in bloating, 92% in belching, 88%
in flatulence, 90.9% in diarrhea and 86.9% in constipation.  No
clinically evident side effects were observed.

Read More At:
http://www.***.com/